CompletedNCT04669665
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
This study evaluated the safety and effectiveness of SLS-002 for people with depression.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SLS-002 for people with depression.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Orange and 20 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 17, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 164
- Sponsor
- Seelos Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- DEVICE, Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04669665
- Official title
Show the full official title
A 2-part Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) Administered to Adults With Major Depressive Disorder at Imminent Risk of Suicide
Get this study by email
Recruitment & locations
CompletedOrange · Panorama City · San Diego
18 more locations
- Hollywood
- Miami
- Miami Lakes
- Miramar
- Oakland Park
- Atlanta
- Decatur
- Springfield
- Gaithersburg
- Flowood
- Buffalo
- Cincinnati
- North Canton
- DeSoto
- Houston
- Richardson
- Salt Lake City
- Morgantown
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SLS-002 for people with depression.
Who is behind this study?
The study sponsor is Seelos Therapeutics, Inc.
Did this study involve medication?
Yes. The study involved medication, including SLS-002 and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
